GPC3 and hepatocellular carcinoma: In another phase I clinical trial, a GPC3-derived peptide vaccine was used in 33 patients with advanced HCC and reported that the vaccine was well-tolerated and elicited a high rate of GPC3-specific CTL responses (106).